Butodesnitazene
 | |
| Identifiers | |
|---|---|
| |
| Chemical and physical data | |
| Formula | C24H33N3O |
| Molar mass | 379.548 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Butodesnitazene is a benzimidazole derivative with opioid effects, which has been sold as a designer drug. It was identified by drug checking services in New Zealand in 2025, having been sold on the black market misrepresented as heroin. Its pharmacological properties have not been studied, although based on the known structure-activity relationships of the benzimidazole opioids, it is expected to have comparatively low potency.[1]
See also
[edit]References
[edit]- ↑ Mayer A, Montgomery N, Hughes E, Birks Ang B, Johnson OE (February 2026). "Detection and characterisation of a new nitazene analogue, butodesnitazene: A collaborative approach to the identification of novel psychoactive substances through Drug Checking". Forensic Science International. 378 112717. doi:10.1016/j.forsciint.2025.112717. PMID 41240498.
 | This analgesic-related article is a stub. You can help Wikipedia by adding missing information. |